Commercial markups on pediatric oncology drugs at 340B pediatric hospitals
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Ian T T Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Hospitals, Pediatric, Antineoplastic Agents, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Arnold Ventures, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Eligible pediatric hospitals can purchase clinician‐administered drugs at discounted rates through the 340B Drug Pricing Program and charge payers prices exceeding drug acquisition costs, but the magnitude of these markups is not known. In a study of newly approved oncology drugs at pediatric 340B hospitals, median negotiated prices ranged from 102% (interquartile range [IQR]: 91%–156%) of average sales price (ASP) at Phoenix Children's Hospital to 630% (IQR: 526%–630%) at Driscoll Children's Hospital. Pediatric hospitals participating in the federal 340B Drug Pricing Program can extract steep payments on new drugs from commercial insurers, though with wide variation between and within hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Ian T T Liu, William B Feldman
Förderung
- NHLBI NIH HHS
- Arnold Ventures
- National Heart, Lung, and Blood Institute
Zitieren
APA
Liu, I. T. T., Wang, J., Sarpatwari, A., Kesselheim, A. S., & Feldman, W. B. (2024). Commercial markups on pediatric oncology drugs at 340B pediatric hospitals. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31158
Vancouver
Liu ITT, Wang J, Sarpatwari A, Kesselheim AS, Feldman WB. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31158
BibTeX
@article{Liu2024,
author = {Liu, Ian T T and Wang, Junyi and Sarpatwari, Ameet and Kesselheim, Aaron S and Feldman, William B},
title = {Commercial markups on pediatric oncology drugs at 340B pediatric hospitals},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31158}
}
EUVIMED